Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Chemical drugs | 1 |
Top 5 Target | Count |
---|---|
3Cpro x SARS-CoV-2 3CLpro | 1 |
VMAT1 x VMAT2 | 1 |
Mechanism 3Cpro inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism VMAT1 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV 3CLpro inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Jul 2021 |
Sponsor / Collaborator |
Start Date03 Jan 2020 |
Sponsor / Collaborator |
Start Date03 Jul 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
GC-373 ( 3Cpro x SARS-CoV-2 3CLpro ) | Norovirus Infections More | Preclinical |
VMAT inhibitors(Wichita State University) ( VMAT1 x VMAT2 ) | - | Preclinical |
GC-375 ( SARS-CoV-2 3CLpro ) | Norovirus Infections More | Pending |
Compound 8a(Wichita State University) ( SARS-CoV-2 3CLpro ) | Norovirus Infections More | Pending |